- Home
- / SBW Life Sciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
SBW Life Sciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩640
2024-10-29
Market Capitalization
₩121.6 B
2024-07-23
Revenue
₩60 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 61.1B | 52.6B | 57.0B | 51.5B | 50.9B | 48.3B | 60.0B |
| Cost of goods sold | 44.4B | 41.6B | 36.2B | 34.5B | 29.0B | 39.5B | 46.7B |
| Gross profit | 17.7B | 14.1B | 22.0B | 17.2B | 22.1B | 9.2B | 14.2B |
| Gross profit margin, % | 26.8% | 38.6% | 33.5% | 43.4% | 19.1% | 23.6% | |
| Operating expense total | 16.0B | 22.2B | 14.8B | 14.1B | 14.7B | 8.3B | 7.8B |
| Depreciation and amortization | 3.9B | 6.8B | 5.4B | 19.5B | 7.7B | 4.9B | 8.3B |
| EBITDA | 1.7B | (8.1B) | 7.2B | 3.1B | 7.4B | 915.5M | 8.0B |
| EBITDA margin, % | -15.4% | 12.7% | 6.0% | 14.6% | 1.9% | 13.3% | |
| EBIT | (4.3B) | (15.4B) | 29.8M | (17.7B) | (3.0B) | (4.3B) | (3.2B) |
| EBIT margin, % | -29.3% | 0.1% | -34.4% | -5.9% | -8.8% | -5.3% | |
| Interest income | 278.3M | 154.6M | 443.7M | 148.1M | 142.1M | 411.9M | 353.2M |
| Interest expense | 4.4B | 2.8B | 1.8B | 4.2B | 5.2B | 5.7B | 3.8B |
| Pre tax profit | (13.3B) | (16.3B) | (1.8B) | (27.2B) | (15.9B) | (7.8B) | (7.2B) |
| Income tax expense | 203.7M | 336.8M | (185.2M) | 694.3M | |||
| Net Income | (13.5B) | (16.3B) | (1.8B) | (27.5B) | (15.9B) | (7.7B) | (7.9B) |